{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/management/infected-eczema/","result":{"pageContext":{"chapter":{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema","depth":2,"htmlHeader":"<!-- begin field 1ec142ff-6429-413c-b57e-f4d51b6dba55 --><h2>Scenario: Infected eczema</h2><!-- end field 1ec142ff-6429-413c-b57e-f4d51b6dba55 -->","summary":"Covers the additional management of infected eczema (indicated by areas of weeping, crusting, or pustules; fever or malaise; rapidly worsening eczema; or eczema that has failed to respond to treatment) with antibiotics and/or antiseptics.","htmlStringContent":"<!-- begin item c0b4d406-4b30-42b6-8b55-e7c8fdbf82e8 --><!-- begin field ca8fdb57-bb4a-4aa7-a968-acbd00858165 --><p>From age 1 month onwards.</p><!-- end field ca8fdb57-bb4a-4aa7-a968-acbd00858165 --><!-- end item c0b4d406-4b30-42b6-8b55-e7c8fdbf82e8 -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a9dce971-0c2d-548c-9579-e73da837aaf1","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field f01f8460-b54c-40b4-b4bd-a71400b20551 --><h3>How should I manage infected eczema?</h3><!-- end field f01f8460-b54c-40b4-b4bd-a71400b20551 -->","summary":null,"htmlStringContent":"<!-- begin item f1df1803-65ba-429d-a5dc-a71400b20161 --><!-- begin field fcbaab95-bdab-4c34-b5f3-a71400b20551 --><ul><li><strong>Consider the need for admission or referral.</strong><ul><li>Admit to hospital if <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/background-information/complications/\">eczema herpeticum</a> (widespread herpes simplex virus) is suspected.</li></ul></li><li><strong>Prescribe appropriate treatment.</strong><ul><li><strong>If there are extensive areas of infected eczema,</strong> swab the skin and prescribe an oral antibiotic. Routine swabbing of skin that is not infected is <em>not </em>recommended.<ul><li>Flucloxacillin is the first-line choice.</li><li>Prescribe erythromycin if the person has an allergy to penicillin or if there is known resistance to flucloxacillin. If the person has previously been unable to tolerate erythromycin because of nausea or cramps, consider prescribing clarithromycin.</li><li>If the infection responds poorly to the first-line antibiotic, prescribe an alternative antibiotic, if necessary, according to the swab results, or seek specialist advice.</li></ul></li><li><strong>If there are localized areas of infection,</strong> consider prescribing a topical antibiotic.<ul><li>Creams or ointments containing antibiotics can be used as separate products or combined with a corticosteroid. Avoid using combined corticosteroid/antibiotic preparations on a regular basis as this will increase the risk of antibiotic resistance.</li><li>Advise that topical antibiotics should be used for no longer than 2 weeks.</li></ul></li><li>For more information on using antibiotics, see the prescribing information sections on <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/oral-antibiotics/\">Oral antibiotics</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/prescribing-information/topical-antibiotics-antiseptics/\">Topical antibiotics and antiseptics</a>.</li></ul></li><li><strong>Offer treatment and advice to reduce the risk of further infection.</strong><ul><li>Prescribe new supplies of topical products (emollients and corticosteroids) for use after the infection has cleared, and advise the person to discard the old products.</li><li>Consider advising the use of a topical antiseptic preparation (for example chlorhexidine or triclosan) as an adjunct to standard treatment, to reduce the bacterial load in areas that are prone to infection.</li></ul></li><li><strong>Episodes of infected eczema usually co-exist with a flare and will require concomitant treatment at the appropriate treatment step.</strong> See <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/mild-eczema/\">Scenario: Mild eczema</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/moderate-eczema/\">Scenario: Moderate eczema</a>, or <a class=\"topic-reference internal-reference\" href=\"/topics/eczema-atopic/management/severe-eczema/\">Scenario: Severe eczema</a> for management information.</li><li><strong>Refer urgently (within 2 weeks) to a dermatologist if </strong>infected eczema has not responded to treatment.</li><li><strong>Refer routinely to a dermatology department if:</strong><ul><li>The diagnosis is, or has become, uncertain.</li><li>Eczema is associated with severe and recurrent infections, especially deep abscesses or pneumonia.</li></ul></li></ul><!-- end field fcbaab95-bdab-4c34-b5f3-a71400b20551 --><!-- end item f1df1803-65ba-429d-a5dc-a71400b20161 -->","subChapters":[{"id":"0ddfb8b1-1de7-5b14-9fb0-d4dcee06ed6b","slug":"basis-for-recommendation-1e9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 728df650-b5c6-47e6-886c-a71400b20555 --><h4>Basis for recommendation</h4><!-- end field 728df650-b5c6-47e6-886c-a71400b20555 -->","summary":null,"htmlStringContent":"<!-- begin item 1e940614-1987-43f9-bf2e-a71400b20555 --><!-- begin field e19cf868-b3a8-4726-997d-a71400b20555 --><p>These recommendations are largely based on expert opinion in the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].<em> </em>NICE reviewed this guideline in July 2016 and found no new evidence to warrant a change in recommendations. CKS has extrapolated the recommendations to include the management of older children and adults.</p><p>These recommendations are also in line with those in <em>Management of atopic eczema in primary care </em>published by the Scottish Intercollegiate Guideline Network (SIGN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>], <em>Atopic eczema</em> published by the Primary Care Dermatology Society (PCDS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>], and in review articles on atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Baron, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Eichenfield, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">BMJ, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tott&eacute;, 2016</a>].</p><h5>Immediate admission</h5><ul><li>Eczema herpeticum is potentially life-threatening condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>]. If suspected, prompt emergency admission should be arranged for confirmation of the diagnosis and antiviral treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</li></ul><h5>Prescribing appropriate treatment</h5><ul><li><strong>Oral antibiotics</strong><ul><li>Evidence to support the effectiveness of oral antibiotics in the treatment of visibly infected atopic eczema is limited due to a lack of high-quality studies. However, clinical experience indicates that treatment of grossly infected skin is usually warranted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Hoare et al, 2000</a>]. Expert opinion in a review article is that short courses of oral antibiotics are recommended if there is widespread, infected eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>].</li><li>Expert opinion in the SIGN guideline is that oral antibiotics are not recommended in the routine treatment of non-infected atopic eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].</li></ul></li><li><strong>Choice of antibiotic </strong><ul><li>Flucloxacillin is the drug of choice for the treatment of atopic eczema that is visibly infected. It is a narrow-spectrum beta-lactam antibiotic with good activity against <em>Staphylococcal aureus</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>], which is the most common causative pathogen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Lyons, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tott&eacute;, 2016</a>].</li><li>A macrolide is a suitable alternative if penicillins are contraindicated.<ul><li>Erythromycin is commonly used, although nausea is a common adverse effect that may limit use.</li><li>Clarithromycin is an alternative to erythromycin that is reputed to cause less adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">DTB, 1991</a>].</li></ul></li></ul></li><li><strong>Topical antibiotics</strong><ul><li>There is a lack of evidence from controlled trials to support the use of topical antibiotics to treat infected atopic eczema, with only one randomized controlled trial investigating this. Data from trials that compared the use of topical antibiotic and corticosteroid combination products have not shown that addition of the antibiotic component provides benefit beyond that of a corticosteroid alone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Hoare et al, 2000</a>].</li><li>Despite the limited evidence to support their use, NICE considers that it is worth trialing these products on an individual basis if the area of infected eczema is localized. Their use should be restricted to a maximum of 2 weeks, however, because of concerns of bacterial resistance and the risks of sensitization [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>].</li></ul></li><li><strong>Swabbing</strong><ul><li>Following advice from experts, CKS recommends swabbing all people with infected eczema <em>before </em>treatment with an oral antibiotic is started. This will allow for early detection of resistant staphylococcal species (including meticillin resistant <em>S. aureus </em>[MRSA]) and beta haemolytic streptococci species, which may influence subsequent management.<ul><li>Note that this recommendation is not in full agreement with the NICE or SIGN guideline development groups (GDGs), who recommend swabbing only if there is recurrent infection or other reason to believe there is involvement of resistant or atypical organisms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].</li><li>Expert opinion in a guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>] and reveiw article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] is that obtaining swabs from affected skin and nares may be helpful to identify infection and direct further management.</li></ul></li><li>The recommendation that routine swabbing of non–clinically infected skin should not be undertaken is based on the SIGN guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>].</li></ul></li></ul><h5>Reducing the risk of further infection</h5><ul><li>These recommendations are based on expert opinion in the NICE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">National Collaborating Centre for Women's and Children's Health, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">NICE, 2007a</a>] and the SIGN guideline  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">SIGN, 2011</a>]. <ul><li>Topical corticosteroids and emollients should be discarded after the infection has cleared, as pathogens can contaminate them and survive in product packaging. This applies particularly to creams packaged in tubs and tubes, although the risk is probably less with pump-dispensers.</li><li>There is only limited evidence from controlled trials to support the effectiveness of topical antiseptics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Hoare et al, 2000</a>]; however, they are recommended by NICE to reduce bacterial load in infection-prone areas on the basis of clinical experience. Routine use of emollients containing antiseptics is not recommended.</li><li>Encouraging the person to keep their skin in good condition by the appropriate use of emollients and other products, and the avoidance of trigger factors will help reduce the frequency of flares and infection.</li></ul></li></ul><h5>Referral</h5><ul><li>The NICE GDG could not find any clinical evidence or evidence on cost-effectiveness in relation to referral and treatment outcomes for eczema. These recommendations are therefore based on referral advice from other guidance and the GDG's collective experience. <ul><li>The recommendations are also in line with recommendations in a guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Primary Care Dermatology Society, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Arkwright, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Tollefson, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/eczema-atopic/references/\">Strathie, 2016</a>] on atopic eczema.</li></ul></li><li>These recommendations are designed to reflect current clinical practice, ensuring that people who require a referral are referred more promptly and that inappropriate referrals are minimized.</li></ul><!-- end field e19cf868-b3a8-4726-997d-a71400b20555 --><!-- end item 1e940614-1987-43f9-bf2e-a71400b20555 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}